Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021
24 November 2021 - 12:00AM
Vaxart, Inc. (NASDAQ: VXRT) today announced that Dr. Sean Tucker,
SVP and Chief Scientific Officer, will present at the World Vaccine
& Immunotherapy Congress West Coast 2021 in San Diego on
Tuesday, November 30, 2021 at 2:40 p.m. PT.
Dr. Tucker will provide an overview of Vaxart’s development
program for its oral tablet COVID-19 vaccine candidate.
Vaxart’s oral tablet COVID-19 vaccine is the only oral COVID-19
vaccine about which there is clinical data supporting its
immunological potential and the only one currently in Phase II
clinical trials, which started in October 2021.
About VaxartVaxart is a clinical-stage
biotechnology company developing a range of oral recombinant
vaccines based on its proprietary delivery platform. Vaxart
vaccines are designed to be administered using tablets that can be
stored and shipped without refrigeration and eliminate the risk of
needle-stick injury. Vaxart believes that its proprietary tablet
vaccine delivery platform is suitable to deliver recombinant
vaccines, positioning the company to develop oral versions of
currently marketed vaccines and to design recombinant vaccines for
new indications. Vaxart's development programs currently include
tablet vaccines designed to protect against coronavirus, norovirus,
seasonal influenza, and respiratory syncytial virus (RSV), as well
as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's
first immuno-oncology indication. Vaxart has filed broad domestic
and international patent applications covering its proprietary
technology and creations for oral vaccination using adenovirus and
TLR3 agonists.
Note Regarding Forward-Looking
Statements This press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements, other than statements of historical facts, included in
this press release regarding Vaxart's strategy, prospects, plans
and objectives, results from pre-clinical and clinical trials,
commercialization agreements and licenses, and beliefs and
expectations of management are forward-looking statements. These
forward-looking statements may be accompanied by such words as
"should," "believe," "could," "potential," "will," "expected,"
"plan," and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements
relating to Vaxart's ability to develop and commercialize its
product candidates, including its vaccine booster products;
Vaxart's expectations regarding clinical results and trial data;
and Vaxart's expectations with respect to the effectiveness of its
product candidates. Vaxart may not actually achieve the plans,
carry out the intentions, or meet the expectations or projections
disclosed in the forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans,
intentions, expectations, and projections disclosed in the
forward-looking statements. Various important factors could cause
actual results or events to differ materially from the
forward-looking statements that Vaxart makes, including
uncertainties inherent in research and development, including the
ability to meet anticipated clinical endpoints, commencement,
and/or completion dates for clinical trials, regulatory submission
dates, regulatory approval dates, and/or launch dates, as well as
the possibility of unfavorable new clinical data and further
analyses of existing clinical data; the risk that clinical trial
data are subject to differing interpretations and assessments by
regulatory authorities; whether regulatory authorities will be
satisfied with the design of and results from the clinical studies;
decisions by regulatory authorities impacting labeling,
manufacturing processes, and safety that could affect the
availability or commercial potential of any product candidate,
including the possibility that Vaxart's product candidates may not
be approved by the FDA or non-U.S. regulatory authorities; that,
even if approved by the FDA or non-U.S. regulatory authorities,
Vaxart's product candidates may not achieve broad market
acceptance; that a Vaxart collaborator may not attain development
and commercial milestones; that Vaxart or its partners may
experience manufacturing issues and delays due to events within, or
outside of, Vaxart's or its partners' control; difficulties in
production, particularly in scaling up initial production,
including difficulties with production costs and yields, quality
control, including stability of the product candidate and quality
assurance testing, shortages of qualified personnel or key raw
materials, and compliance with strictly enforced federal, state,
and foreign regulations; that Vaxart may not be able to obtain,
maintain, and enforce necessary patent and other intellectual
property protection; that Vaxart's capital resources may be
inadequate; Vaxart's ability to resolve pending legal matters;
Vaxart's ability to obtain sufficient capital to fund its
operations on terms acceptable to Vaxart, if at all; the impact of
government healthcare proposals and policies; competitive factors;
and other risks described in the "Risk Factors" sections of
Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart
does not assume any obligation to update any forward-looking
statements, except as required by law.
Contacts
Vaxart Media Relations: |
|
Investor Relations: |
Mark Herr |
|
Andrew Blazier |
Vaxart, Inc. |
|
FINN Partners |
mherr@vaxart.com |
|
IR@Vaxart.com |
(203) 517-8957 |
|
(646) 871-8486 |
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2024 to May 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From May 2023 to May 2024